Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Post by gainwidpatienceon Jun 30, 2018 9:17pm
453 Views
Post# 28256528

Market size of iCo-019 (Oral Amp B) - Billions!!!!

Market size of iCo-019 (Oral Amp B) - Billions!!!!Quote from ICO NR in the past:
Given our significant progress in contract manufacturing and pre-clinical development we have a highly differentiated Oral Amp B lead candidate rapidly making its way into the clinic," stated Andrew Rae, President and CEO. "Assuming clinical data reflects meaningful pre-clinical outcomes we believe we may address anti-fungal markets in excess of a billion dollars with an asset that makes administration far more accessible to a broad population."

Important info from the link given in the NR:

Highlights
- The global market for antifungal drugs was valued at $13.1 billion in 2016. The market should reach $16.1 billion by 2021, growing at a compound annual growth rate (CAGR) of 4.2% from 2016 to 2021.
- The global market for prescription antifungal drugs was valued at $7.0 billion in 2016. The market should reach $8.3 billion by 2021, growing at a CAGR of 3.5% from 2016 to 2021.
- The global market for over the counter (OTC) antifungal drugs was valued at $6.1 billion in 2016. The market should reach $7.8 billion by 2021, growing at a CAGR of 5.0% from 2016 to 2021.


Links:
https://www.stockhouse.com/news/press-releases/2016/11/28/clarification-ico-therapeutics-announces-positive-study-results-and-significant

https://www.reportbuyer.com/product/2212016/antifungal-drugs-technologies-and-global-markets.html

<< Previous
Bullboard Posts
Next >>